CommunicationBenzofuran-isatin-hydroxylimine/THIOSEMICARBAZIDE (cas 116989-62-9) hybrids: Design, synthesis and in vitro anti-mycobacterial activity evaluation

Add time:08/26/2019    Source:sciencedirect.com

A series of novel benzofuran-isatin-hydroxylimine/thiosemicarbazide hybrids were designed, synthesized and evaluated for their in vitro anti-TB activities against drug-sensitive MTB H37Rv and MDR-TB isolates as well as cytotoxicity. All benzofuran-isatin-hydroxylimine/thiosemicarbazide hybrids exhibited considerable in vitro anti-mycobacterial activities against the tested three MTB strains, and all of them also showed acceptable cytotoxicity. The most active hybrid 7f was >4.8 and >51 folds more potent than the first line anti-TB agents RIF and INH against both drug-sensitive MTB H37Rv and MDR-TB isolates, respectively. The results demonstrated the potential utility of benzofuran-isatin-hydroxylimine/-thiosemicarbazide hybrids as anti-TB agents.

We also recommend Trading Suppliers and Manufacturers of THIOSEMICARBAZIDE (cas 116989-62-9). Pls Click Website Link as below: cas 116989-62-9 suppliers

Prev:Original articleSynthesis, docking and in-vitro screening of mannich bases of THIOSEMICARBAZIDE (cas 116989-62-9) for anti-fungal activity
Next:Vibrational and quantum chemical investigation of cyclization of THIOSEMICARBAZIDE (cas 116989-62-9) group in 1-benzoyl-4-phenyl-3-THIOSEMICARBAZIDE (cas 116989-62-9))